Patents/Assignees

Astrazeneca AB

80 patents in portfolio

US12421208utility2025
Chemical Compounds
0 cites
US12414954utility2025
POLQ Inhibitors
0 cites
US12409174utility2025
Combination of Zibotentan and Dapagliflozin for the Treatment of Endothelin Related Diseases
0 cites
US12409186utility2025
Methods of Treating Chronic Kidney Disease with Dapagliflozin
0 cites
US12410187utility2025
Fused Tricyclic Compounds Useful as Anticancer Agents
0 cites
US12410254utility2025
Treatment of Cardiometabolic Disease with Inhibitors of Type I Interferon Signalling
0 cites
US12364689utility2025
Dosage Regimen for the Treatment of Cancer
0 cites
US12291524utility2025
Amido Heteroaromatic Compounds
0 cites
US12280049utility2025
Methods of Delaying Pain Progression and Treating Prostate Cancer
0 cites
US12274707utility2025
Methods of Treating Chronic Kidney Disease with Dapagliflozin
0 cites
US12264190utility2025
Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors
0 cites
US12252495utility2025
Protein Kinase B Inhibitors
0 cites
US12240832utility2025
IRAK4 Inhibitors
0 cites
US12213988utility2025
Methods of Treating Chronic Kidney Disease with Dapagliflozin
0 cites
US12201638utility2025
Pharmaceutical Compositions Comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
0 cites
US12195485utility2025
Arginase Inhibitors and Methods of Use Thereof
0 cites
US12178876utility2024
Conjugates Comprising Cleavable Linkers
0 cites
US12168766utility2024
Modulators of APOL1 Expression
0 cites
US12121517utility2024
Combination of Zibotentan and Dapagliflozin for the Treatment of Endothelin Related Diseases
0 cites
US12115174utility2024
Dendrimer Formulations
0 cites

← PreviousPage 2 of 4Next →